CD4 and type 1 diabetes mellitus: In sum, these data indicate that targeting glycolysis leads to severe exhaustion of diabetogenic CD4+ T cell clones, and suggest this as the mechanism by which PFK15 treatment delays T1D onset in vivo (Figure 3).